HTDS: MMR Vaccine Passes Chinese SFDA Drug Evaluation
- Posted on 14 January 2010
Hard to Treat Diseases (HTDS) and its China subsidiary Mellow Hope have announced that the MMR vaccine (Measles, Mumps and Rubella Combined Vaccine Live) has obtained a "pass" on its First Drug Evaluation.
The Chinese State Food and Drug Administration (SFDA) held a Drug Evaluation Conference to determine whether the vaccine meets the requirements for release onto the Chinese pharmaceutical market.
Based on the research and clinical trial results presented, the panel agreed that the vaccine has a good safety profile. The vaccine will undergo further inquiry for the final SFDA approval. The First Drug Evaluation panel will submit the results for final approval. This approval will secure the production license for the vaccine.
HTDS' CEO Terry Yuan said, "We are actively preparing for the clinical trial protocol designed exactly as per Chinese actual conditions. Taking the booster immunization into account, it is estimated that the market size in China will be 60 million doses per year."
